This Year's Highlights

• Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (B-CLL) in conjunction with Baylor College of Medicine, initial patients have received cellular product.
• Preclinical program in cell-based therapies for breast cancer at Harvard.
• Signed Technology Licensing Agreements with Geron (February ?06), Sangamo (March ?06) and Medinet (August ?06).

Anticipated Highlights

• Conclude I/II in 2007
• Phase I trials - 2007
• United Therapeutics Phase I pulmonary trial ? Dose first patient ? Q2 2006 using MaxCyte technology in product manufacturing

Corporate Mission

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of partnered and internally developed therapeutic candidates. The Company?s proprietary ex vivo cell loading technology overcomes critical obstacles, such as safety and scalability, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology by outlicensing its technology to four partners for development and commercialization in more than eight therapeutic programs in oncology, pulmonary, metabolic and infection diseases as well as developing three drug candidates for outlicensing in collaboration with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia and two preclinical oncology programs. The Company offers its unparalleled cell loading technology to collaborators who benefit from MaxCyte?s ability to rapidly optimize molecule-cell combinations and dramatically accelerate development timelines for a broad range of indications. Biotech and pharmaceutical partners, including Geron, Sangamo, United Therapeutics, and AlphaVax, are currently working to develop cell therapeutics for pulmonary disease, congestive heart disease, infectious disease and cancer. The Company?s technical team has made significant advances in validating the technology, developing its flexibility and broad applicability and providing for robust and fully reproducible performance. Ultimately, MaxCyte was the first company to bring flow electroporation into the clinic. The cell processing system has received Master File designation with the CBER Division of the U.S. FDA and has been cleared by NIH?s RAC and Health Canada. The MaxCyte system can be used to develop cell therapeutics for a variety of diseases and can be used to load cells for both autologous and allogeneic therapies.